AstraZeneca Exanta For Prevention Of Thromboembolism Goes To Cmte. In September
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is also seeking an indication for longer term secondary prevention of venous thromboembolism. Phase III results show oral direct thrombin inhibitor is equal to or better than warfarin, without dose adjustment.